Short-course moxifloxacin therapy in the treatment of community-acquired pneumonia
Abstract
Objective To evaluate the efficacy,safety of short-course moxifloxacin therapy in the treatment of community-acquired pneumonia.Methods This analysis was based on the outcomes in 87 patients with mild to moderate community-acquired pneumonia.Patients were randomized to receive moxifloxacin therapy for 10 days(control group) or 5 days(short-course therapy group).Results ①The overall cure rates and efficacy rates were 68.2% and 90.9% in control group,65.1% and 88.4% in short-course therapy group,respectively.The bacterial clearance rates were 88.2% in control group and 87.9% in short-course therapy group,respectively.There was no significant difference between the two groups in the above results(P0.05).②The incidences of adverse drug reaction were 9.1% in control group and 7.0% in short-course therapy group,respectively.There was no significant difference between the two groups(P0.05).Conclusion The short-course moxifloxacin therapy in the treatment of community-acquired pneumonia was as effective and safe as the standard therapy.
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 87 participants or records.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.